The Wire

Researchers from the Australian Centre for Blood Diseases at Monash University have published their latest study paper in Haematologica, that describes how a novel antibody can be engineered to detect and block formation of blood clots including thrombosis.

Their findings also suggests testing pathological properties against the Von Willebrand Factor (VWF) blood protein with existing antibodies to identify optimal ones under pathological blood clotting conditions.

This would allow clinicians to purposely design effective first-in-class anti-platelet therapies to prevent dangerous, adversive side effects for patients who undergo this treatment such as heart attack, stroke or severe bleeding complications.